ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX) and treatment"

  • Abstract Number: 2264 • 2018 ACR/ARHP Annual Meeting

    Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases

    Anna Postolova1 and Mark C. Genovese2, 1Department of Medicine, Stanford University Medical Center, Palo Alto, CA, 2Department of Medicine, Stanford University, Palo Alto, CA

    Background/Purpose: Granulomatous Mastitis is a rare, inflammatory disease of the breast. Presenting symptoms in the breast can be unilateral or bilateral pain, masses, skin induration,…
  • Abstract Number: 2747 • 2018 ACR/ARHP Annual Meeting

    Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival

    Stig Tengesdal and Geirmund Myklebust, Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway

    Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy…
  • Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting

    Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be

    Ignacio Castaño1, Irene Monjo2, Alejandro Balsa3, Diana Peiteado2, Sara García-Carazo4 and Eugenio De Miguel1, 1Medicine, Universidad Autonoma Madrid, MADRID, Spain, 2Rheumatology, Hospital Universitario La Paz, MADRID, Spain, 3Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, 4Rheumatology, La Paz University Hospital, Madrid, Spain

    Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…
  • Abstract Number: 1419 • 2017 ACR/ARHP Annual Meeting

    Characteristics of Patients with Early Rheumatoid Arthritis Who Have a Delayed Response to Treatment with Methotrexate in Monotherapy or in Combination with Adalimumab

    Josef S. Smolen1, Xianwei Bu2, Xin Wang2, Jessica L. Suboticki3 and Arthur Kavanaugh4, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., Mettawa, IL, 4Medicine, University of California, San Diego, La Jolla, CA

    Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), treat-to-target recommendations call for adjustment of treatment if a target is not met within 3-6 months (mths)…
  • Abstract Number: 2279 • 2017 ACR/ARHP Annual Meeting

    Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept

    Ekaterina Alexeeva1,2, Tatiana Dvoryakovskaya1,2, Victor Gladkikh3,4, Andrei Moskalev4,5, Rina Denisova2, Ksenia Isaeva2, Olga Lomakina2, Margarita Soloshenko2 and Anna Karaseva2, 1Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, 2Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, 3Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, 4Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, 5Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation

    Background/Purpose: The effectiveness of target use of biological medications depends on how personalized they are to fit patient’s individual parameters with juvenile idiopathic arthritis (JIA).…
  • Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium

    The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA

    Joost Swart1, Nico Wulffraat2, Sytze de Roock3 and Pieter van Dijkhuizen4, 1Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, 2Wilhelmina Children’s Hospital, Utrecht, Netherlands, 3Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…
  • Abstract Number: 606 • 2015 ACR/ARHP Annual Meeting

    Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients

    Paul Studenic1, Farideh Alasti1, Josef S. Smolen2,3, Helmuth Haslacher4 and Daniel Aletaha5, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 32nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 4Laboratory Medicine, Medical University Vienna, Vienna, Austria, 5Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: Methotrexate (MTX) and leflunomide are categorized as DMARDs of first choice in treating rheumatoid arthritis patients. MTX should be used cautiously in patients with…
  • Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting

    A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study

    Petra C.E. Hissink Muller1,2, D.M.C. Brinkman1,3, Dieneke Schonenberg4, Yvonne Koopman-Keemink5, J. Merlijn Van den Berg6, W.P. Bekkering7, Marion van Rossum8,9, Lisette WA van Suijlekom-Smit10, Cornelia F. Allaart11 and Rebecca ten Cate1, 1Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Pediatric Rheumatology, Reade, Amsterdam, Netherlands, 3Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 5Pediatrics, Haga ziekenhuis, The Hague, Netherlands, 6Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 7Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, 8Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 9Reade, Amsterdam, Netherlands, 10Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, 11Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology